SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 20, 2018

Primary Completion Date

August 4, 2021

Study Completion Date

August 4, 2021

Conditions

Small-cell Lung Cancer

Interventions

DRUG

SHR-1210

A humanized anti-PD-1 monoclonal antibody

DRUG

Apatinib

A tyrosine kinase inhibitor selectively targeting VEGFR-2

Trial Locations (2)

Cancer Hospital Chinese Academy of Medical Science, Beijing

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03417895 - SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy | Biotech Hunter | Biotech Hunter